1 Associate Professor, Department of Pharmaceutics, Narasaraopeta Institute of Pharmaceutical Sciences, Narasaraopet, Palnadu, Andhra Pradesh, India.
2 Principal & Professor, Department of Pharmaceutics, Narasaraopeta Institute of Pharmaceutical Sciences, Narasaraopet, Palnadu, Andhra Pradesh, India.
3 Research Scholar, Department of Pharmaceutics, Narasaraopeta Institute of Pharmaceutical Sciences, Narasaraopet, Palnadu, Andhra Pradesh, India.
Research Article
World Journal of Advanced Research and Reviews, 2024, 23(03), 2260-2266
Received on 07 August 2024; revised on 17 September 2024; accepted on 19 September 2024
Ulcers are characterized histologically as lesions that penetrate through the muscularis mucosae into the submucosal layer, affecting any segment of the gastrointestinal (GI) tract mucosa. They often arise due to excessive acid production from peptic secretions. Nizatidine (NZT) is a potent H2-receptor antagonist used to reduce basal, nocturnal, and stimulated gastric acid secretion. This medication is commonly prescribed for conditions such as gastroesophageal reflux disease, peptic ulcers, and duodenal ulcers.
As a member of the histamine H2 receptor antagonist class introduced before proton pump inhibitors, Nizatidine is noted for its effectiveness comparable to ranitidine. However, Nizatidine is distinguished by its thiazole ring, in contrast to the furan ring found in ranitidine. When administered orally, Nizatidine, especially in combination with antacids, enhances drug delivery to parietal cell receptors, improving the overall bioavailability of the medication and its ability to suppress acid secretion.
Nizatidine is primarily absorbed in the proximal small intestine, exhibiting about 70% absolute bioavailability. Its lower absorption from the colon and a short biological half-life (ranging from 1 to 1.6 hours) suggest the potential benefits of developing sustained-release formulations such as floating gels to prolong its therapeutic effects. Clinical studies indicate that Nizatidine, in doses of 300 mg at bedtime or 150 mg twice daily, shows superior efficacy compared to other H2-receptor antagonists for managing duodenal and gastric ulcers as well as gastroesophageal reflux disease.
Nizatidine (NZT); Histamine H2 receptor antagonist; Floating Gel; Bioavailability; Gastro esophageal reflux disease (GERD); Peptic ulcer; and duodenal ulcer
Preview Article PDF
K Venkata Gopaiah, Ramya Teja Medarametala, JN Suresh Kumar, Chilakala Sahithi, Dhanankula Eswari Sai Prasanna, Gali Sathwik, Gongati Sravani and Kalluri Murali. Comprehensive analysis of nizatidine: Pharmacodynamics and pharmacokinetics in anti-ulcer treatment. World Journal of Advanced Research and Reviews, 2024, 23(3), 2260-2266. Article DOI: https://doi.org/10.30574/wjarr.2024.23.3.2855